Imugene Limited
IUGNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | 1.70 | -0.38 |
| FCF Yield | -79.68% | -25.01% | -5.32% | -2.81% |
| EV / EBITDA | -1.51 | -2.32 | -8.58 | -28.42 |
| Quality | ||||
| ROIC | -102.45% | -121.22% | -14.36% | -18.03% |
| Gross Margin | 100.00% | 100.00% | 81.29% | 81.44% |
| Cash Conversion Ratio | – | 0.68 | 0.79 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -28.00% | -27.37% | 17.65% | 46.39% |
| Free Cash Flow Growth | 17.25% | -265.36% | 3.71% | -66.48% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 0.62 | 3.22 | 2.81 |
| Interest Coverage | 0.00 | -321.34 | -1,448.56 | -2,793.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -2.62 | 0.00 | 0.00 |
| Cash Conversion Cycle | 831.61 | 414.62 | -12.55 | -325.10 |